Extravasation GuideTissue injury risk of antineoplastic extravasation

Ifosfamide

Ifosfamida

Risk class

Irritant

If it extravasates

Compress

Cold

References

Risk class: IrritantESMO-EONS 2012 (Table 1, p. vii167); JSCN/JSMO/JASPO 2024 (Table 2)

Compress: coldESMO-EONS 2012 (Fig. 1, p. vii170)

Not classified in: ONS/ASCO 2025

Details by guideline

Risk class in extravasation

ESMO-EONS 2012Irritant
Irritants › Alkylating agents
Table 1, p. vii167
JSCN/JSMO/JASPO 2024Irritant
Table 2

Not classified in: ONS/ASCO 2025

Compress

ESMO-EONS 2012Cold compress
"Localize and neutralize"Anthracyclines; Antibiotics (Mitomycin / Dactinomycin); Alkylating agents
Figure 1, p. vii170

Brand names (ANVISA, Brazil) · DCB (Brazil)

DCB (Brazil)ifosfamida (nº 4807)

Brand names (ANVISA, Brazil)EVOLOX, HOLOXANE, LIFOS

General recommendations of the guidelines

ONS/ASCO 2025Recommendation 1 · Strong; very low
Use antidotes, when one exists, for vesicants and irritants with vesicant properties, rather than no antidote.
Table 3, p. 388
ONS/ASCO 2025Recommendation 3 · Conditional; very low
Thermal compress (cold or warm depending on the agent) rather than no compress.
Table 3, p. 388
ONS/ASCO 2025Recommendation 4 · Conditional; very low
Compress for more than 24 hours rather than 24 hours or less.
Table 3, p. 388
ONS/ASCO 2025Recommendation 5 · Conditional; very low
Central line extravasation: surgical referral or escalation of care in addition to conservative management.
Table 3, p. 388
JSCN/JSMO/JASPO 2024CQ10a · Recommend (weak)
Cold compression (weak recommendation).
Table 1, CQ10a
JSCN/JSMO/JASPO 2024CQ10b · Not recommend (weak); D
Non-use of warm compresses (weak recommendation).
Table 1, CQ10b

Search another drug